Table 2.
Associations between body composition parameters and clinicopathologic variables for patients with esophagogastric cancer
| Variable | Subcutaneous fat index | p valuea | Visceral fat index | p valuea | Skeletal muscle index | p valuea | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Low n (%) | Medium n (%) | High n (%) | Low n (%) | Medium n (%) | High n (%) | Normal n (%) | Sarcopenia n (%) | ||||
| Age (years) | |||||||||||
| ≤64 | 13 (34) | 15 (45) | 18 (49) | 0.560 | 20 (53) | 14 (37) | 12 (38) | 0.533 | 37 (44) | 9 (39) | 0.744 |
| 65–74 | 16 (42) | 10 (30) | 14 (38) | 11 (29) | 17 (45) | 12 (38) | 32 (38) | 8 (35) | |||
| ≥75 | 9 (24) | 8 (24) | 5 (14) | 7 (18) | 7 (18) | 8 (25) | 16 (19) | 6 (26) | |||
| Tumour (T) stage | |||||||||||
| 0/1 | 8 (21) | 5 (15) | 9 (24) | 0.742 | 6 (16) | 7 (18) | 9 (28) | 0.534 | 21 (25) | 1 (4) | 0.033 |
| 2 | 4 (11) | 9 (27) | 5 (14) | 5 (13) | 9 (24) | 4 (13) | 13 (15) | 5 (22) | |||
| 3 | 22 (58) | 17 (52) | 20 (54) | 23 (61) | 18 (47) | 18 (56) | 47 (55) | 12 (52) | |||
| 4 | 4 (11) | 2 (6) | 3 (8) | 4 (11) | 4 (11) | 1 (3) | 4 (5) | 5 (22) | |||
| Nodal (N) stage | |||||||||||
| 0 | 17 (45) | 13 (39) | 20 (54) | 0.776 | 13 (34) | 15 (39) | 22 (69) | 0.103 | 41 (48) | 9 (39) | 0.362 |
| 1 | 12 (32) | 13 (39) | 10 (27) | 14 (37) | 15 (39) | 6 (19) | 29 (34) | 6 (26) | |||
| 2 | 9 (24) | 7 (21) | 7 (19) | 11 (29) | 8 (21) | 4 (13) | 15 (18) | 8 (35) | |||
| TNM stage | |||||||||||
| I | 9 (24) | 10 (30) | 11 (30) | 0.846 | 6 (16) | 11 (29) | 13 (41) | 0.136 | 27 (32) | 3 (13) | 0.175 |
| II | 16 (42) | 11 (33) | 16 (43) | 15 (39) | 16 (42) | 12 (38) | 33 (39) | 10 (43) | |||
| III | 13 (34) | 12 (36) | 10 (27) | 17 (45) | 11 (29) | 7 (22) | 25 (29) | 10 (43) | |||
| Neoadjuvant therapy | |||||||||||
| Yes | 18 (47) | 8 (24) | 17 (46) | 0.090 | 9 (24) | 20 (53) | 14 (44) | 0.031 | 34 (40) | 9 (39) | 0.940 |
| No | 20 (53) | 25 (76) | 20 (54) | 29 (76) | 18 (47) | 18 (56) | 51 (60) | 14 (61) | |||
| Adjuvant therapy | |||||||||||
| Yes | 17 (45) | 10 (30) | 15 (41) | 0.446 | 18 (47) | 13 (34) | 11 (34) | 0.412 | 30 (35) | 12 (52) | 0.141 |
| No | 21 (55) | 23 (70) | 22 (59) | 20 (53) | 25 (66) | 21 (66) | 55 (65) | 11 (48) | |||
| Lymphovascular invasion | |||||||||||
| Yes | 17 (45) | 13 (39) | 21 (57) | 0.324 | 21 (55) | 16 (42) | 14 (44) | 0.463 | 38 (45) | 13 (57) | 0.314 |
| No | 21 (55) | 20 (61) | 16 (43) | 17 (45) | 22 (58) | 18 (56) | 47 (55) | 10 (43) | |||
| Anemiab | |||||||||||
| Yes | 17 (45) | 14 (45) | 13 (35) | 0.621 | 19 (50) | 11 (30) | 14 (45) | 0.181 | 33 (39) | 11 (50) | 0.364 |
| No | 21 (55) | 17 (55) | 24 (65) | 19 (50) | 26 (70) | 17 (55) | 51 (61) | 11 (50) | |||
| White cell count (×109/L) | |||||||||||
| <8.5 | 23 (61) | 21 (68) | 26 (70) | 0.840 | 24 (63) | 23 (62) | 23 (74) | 0.736 | 61 (73) | 9 (41) | 0.011 |
| 8.5–11 | 10 (26) | 7 (23) | 6 (16) | 8 (21) | 10 (27) | 5 (16) | 16 (19) | 7 (32) | |||
| >11 | 5 (13) | 3 (10) | 5 (14) | 6 (16) | 4 (11) | 3 (10) | 7 (8) | 6 (27) | |||
| Neutrophil count (×109/L) | |||||||||||
| <7.5 | 29 (76) | 26 (84) | 32 (86) | 0.493 | 30 (79) | 31 (84) | 26 (84) | 0.821 | 73 (87) | 14 (64) | 0.011 |
| ≥7.5 | 9 (24) | 5 (16) | 5 (14) | 8 (21) | 6 (16) | 5 (16) | 11 (13) | 8 (36) | |||
| Lymphocyte count (× 109/L) | |||||||||||
| <1.0 | 7 (18) | 6 (19) | 5 (14) | 0.781 | 7 (18) | 6 (16) | 5 (16) | 0.957 | 14 (17) | 4 (18) | 0.866 |
| ≥1.0 | 31 (82) | 25 (81) | 32 (86) | 31 (82) | 31 (84) | 26 (84) | 70 (83) | 18 (82) | |||
| Albumin (g/L) | |||||||||||
| ≥35 | 31 (82) | 24 (77) | 34 (92) | 0.238 | 31 (82) | 30 (81) | 28 (90) | 0.517 | 74 (88) | 15 (68) | 0.023 |
| <35 | 7 (18) | 7 (23) | 3 (8) | 7 (18) | 7 (19) | 3 (10) | 10 (12) | 7 (32) | |||
TNM tumor-node-metastasis
a p Values represent X 2 tests for a linear trend in categorical variables and Mann–Whitney U tests for continuous variables
bAnemia is defined as <13 g/dL in males, <11.5 g/dL in females